

22 June 2021 EMA/354021/2021 Human Medicines Division

Overview of (invented) names reviewed in May 2021 by the Name Review Group (NRG)

Adopted at the CHMP meeting of 21-24 June 2021

		NRG meeting 16-17 Feb 2021		NRG meeting 20-21 Apr 2021		NRG meeting 26-27 May 2021		NRG meeting 29-30 Jun 2021		NRG meeting 16-17 Sep 2021		NRG meeting 09-10 Nov 2021		2021 total	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	
Proposed (invented) names*	73	33	33	36	24	31	0	0	0	0	0	0	130	100	
Justification for retention of (invented) name **	3	3	2	7	2	0	0	0	0	0	0	0	7	10	

^{*}Includes invented names, INN+MAH/TM and re-use applications.



^{**}In case of objections to the proposed (invented) name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMA website.

	NRG meeting 16-17 Feb 2021		NRG meeting 20-21 Apr 2021		NRG meeting 26-27 May 2021		NRG meeting 29-30 Jun 2021		NRG meeting 16-17 Sep 2021		NRG meeting . 09-10 Nov 2021		2021 total	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Total number of objections raised	69	173	75	92	61	78	0	0	0	0	0	0	205	343
				Crite	rion - Saf	ety conc	erns							
Similarity with other (invented) name	46	119	61	68	45	55	0	0	0	0	0	0	152	242
Conveys misleading therapeutic/pharmaceutical connotations	1	0	1	1	0	0	0	0	0	0	0	0	2	1
Misleading with respect to composition	1	0	0	0	0	0	0	0	0	0	0	0	1	0
				Crite	erion - IN	IN conce	rns							
Similarity with INN	12	8	1	3	2	6	0	0	0	0	0	0	15	17
Inclusion of INN stem	0	0	0	1	0	1	0	0	0	0	0	0	0	2
			Cri	iterion - 0	Other pub	lic healtl	h concer	ns						
Unacceptable qualifiers	2	0	2	0	0	2	0	0	0	0	0	0	4	2
Conveys a promotional message	3	4	3	1	2	5	0	0	0	0	0	0	8	10
Appears offensive or has an inappropriate connotation	1	2	2	0	5	1	0	0	0	0	0	0	8	3
Similarity between name of individual active substance and fixed combinations and/or between fixed combinations	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Similarity between name of prodrug and related active substance	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Others	3	40	6	22	7	8	0	0	0	0	0	0	16	70

See Guideline on the <u>Acceptability of Names for Human Medicinal Products Processed through the Centralised Procedure (EMA/CHMP/287710/2014)</u> for detailed explanations of criteria used.